Oramed Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Oramed Pharmaceuticals has been growing earnings at an average annual rate of 13.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 17.9% per year.
Key information
13.2%
Earnings growth rate
24.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -17.9% |
| Return on equity | 2.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Aug 24
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
May 03Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Dec 22Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality
Sep 21Oramed to hand Korean rights for insulin capsule
Sep 09Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Jul 07Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?
Jun 12Oramed And Oral Insulin: Can This Small Company Really Do It?
Apr 14Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth
Feb 23Oramed And The Hurdles Of Developing Oral Insulin
Dec 23Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
Nov 02Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress
Oct 04We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation
Aug 24Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Jul 21Oramed reaches 50% enrollment in late-stage oral insulin study
Jun 08Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Apr 06Revenue & Expenses Breakdown
How Oramed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | 4 | 6 | 7 |
| 30 Jun 24 | 0 | 21 | 8 | 5 |
| 31 Mar 24 | 1 | 10 | 8 | 6 |
| 31 Dec 23 | 1 | 6 | 8 | 9 |
| 30 Sep 23 | 2 | -16 | 9 | 14 |
| 30 Jun 23 | 3 | -20 | 11 | 19 |
| 31 Mar 23 | 3 | -30 | 11 | 26 |
| 31 Dec 22 | 3 | -37 | 16 | 28 |
| 30 Sep 22 | 3 | -46 | 20 | 32 |
| 30 Jun 22 | 3 | -46 | 19 | 33 |
| 31 Mar 22 | 3 | -40 | 18 | 27 |
| 31 Dec 21 | 3 | -35 | 13 | 27 |
| 30 Nov 21 | 3 | -25 | 8 | 22 |
| 31 Aug 21 | 3 | -22 | 6 | 21 |
| 31 May 21 | 3 | -18 | 4 | 18 |
| 28 Feb 21 | 3 | -15 | 4 | 15 |
| 31 Dec 20 | 3 | -22 | 5 | 21 |
| 30 Nov 20 | 3 | -15 | 4 | 14 |
| 31 Aug 20 | 3 | -12 | 4 | 10 |
| 31 May 20 | 3 | -11 | 4 | 9 |
| 29 Feb 20 | 3 | -13 | 4 | 11 |
| 30 Nov 19 | 3 | -13 | 4 | 11 |
| 31 Aug 19 | 3 | -14 | 4 | 14 |
| 31 May 19 | 3 | -15 | 4 | 14 |
| 28 Feb 19 | 3 | -15 | 4 | 14 |
| 30 Nov 18 | 3 | -14 | 4 | 14 |
| 31 Aug 18 | 2 | -13 | 4 | 12 |
| 31 May 18 | 2 | -12 | 4 | 12 |
| 28 Feb 18 | 2 | -10 | 3 | 10 |
| 30 Nov 17 | 2 | -10 | 3 | 10 |
| 31 Aug 17 | 2 | -10 | 3 | 10 |
| 31 May 17 | 2 | -13 | 2 | 11 |
| 28 Feb 17 | 2 | -13 | 2 | 10 |
| 30 Nov 16 | 1 | -11 | 2 | 8 |
| 31 Aug 16 | 1 | -11 | 2 | 8 |
| 31 May 16 | 0 | -8 | 3 | 6 |
| 29 Feb 16 | 0 | -8 | 3 | 6 |
| 30 Nov 15 | 0 | -8 | 3 | 5 |
| 31 Aug 15 | 0 | -7 | 3 | 5 |
| 31 May 15 | 0 | -7 | 3 | 4 |
| 28 Feb 15 | 0 | -7 | 3 | 4 |
| 30 Nov 14 | 0 | -6 | 3 | 4 |
| 31 Aug 14 | 0 | -6 | 3 | 3 |
| 31 May 14 | 0 | -5 | 2 | 3 |
Quality Earnings: ORMP has a high level of non-cash earnings.
Growing Profit Margin: ORMP became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORMP has become profitable over the past 5 years, growing earnings by 13.2% per year.
Accelerating Growth: ORMP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ORMP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ORMP's Return on Equity (2.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 19:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oramed Pharmaceuticals Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |